Commit and Base excess positive - a phase IV clinical study of FDA data
Summary:
We study 4,851 people who take Commit (nicotine polacrilex) or have Base excess positive. No report of Base excess positive is found in people who take Commit.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Commit?
Commit has active ingredients of nicotine polacrilex. eHealthMe is studying from 4,842 Commit users. Check the latest studies of Commit.
What is Base Excess Positive?
Base excess positive is found to be associated with 10 drugs and 12 conditions by eHealthMe. Check the latest studies of Base excess positive.
No report is found.
Do you take Commit and have Base excess positive?
- Check whether Base excess positive is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Commit:
- Commit (4,842 reports)
Base excess positive treatments and more:
- Base excess positive (9 reports)
How severe was Base excess positive and when was it recovered:
Expand to all the drugs that have ingredients of nicotine polacrilex:
Browse all side effects of Commit:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Base excess positive:
Browse all the conditions that are associated with Base excess positive:
How the study uses the data?
The study uses data from the FDA. It is based on nicotine polacrilex (the active ingredients of Commit) and Commit (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Methadone Hydrochloride cause Sleep Apnea Syndrome? - a second ago
- Klonopin and Drug Abuse for Men aged 30-39 - 2 seconds ago
- Klonopin and Substance Abuse for Men aged 30-39 - 3 seconds ago
- Klonopin and Narcotic Abuse for Men aged 30-39 - 3 seconds ago
- Klonopin and Marijuana Abuse for Men aged 30-39 - 3 seconds ago
- Klonopin and Lsd Abuse for Men aged 30-39 - 4 seconds ago
- Could Alendronate Sodium cause Eye Pain? - 4 seconds ago
- Klonopin and Illicit Drug Abuse for Men aged 30-39 - 4 seconds ago
- Klonopin and Heroin Abuse for Men aged 30-39 - 4 seconds ago
- Klonopin and Hallucinogen Abuse for Men aged 30-39 - 5 seconds ago